Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Enliven Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Enliven Therapeutics, Inc.’s stock price such as:

• Enliven Therapeutics, Inc.’s current stock price and volume
• Why Enliven Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ELVN from analysts
• ELVN’s stock price momentum as measured by its relative strength

About Enliven Therapeutics, Inc. (ELVN)

Before we jump into Enliven Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Want to learn more about Enliven Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Enliven Therapeutics, Inc..

Enliven Therapeutics, Inc.’s Stock Price as of Market Close

As of August 05, 2026, 12:16 PM, CST, Enliven Therapeutics, Inc.’s stock price was $58.040.

Enliven Therapeutics, Inc. is down 5.02% from its previous closing price of $61.110.

During the last market session, Enliven Therapeutics, Inc.’s stock traded between $57.470 and $62.320. Currently, there are approximately 62.80 million shares outstanding for Enliven Therapeutics, Inc..

Enliven Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Enliven Therapeutics, Inc. Stock Price History

Enliven Therapeutics, Inc.’s (ELVN) price is currently up 5.89% so far this month.

During the month of August, Enliven Therapeutics, Inc.’s stock price has reached a high of $62.320 and a low of $52.730.

Over the last year, Enliven Therapeutics, Inc. has hit prices as high as $61.290 and as low as $14.785. Year to date, Enliven Therapeutics, Inc.’s stock is up 276.88%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Enliven Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of August 04, 2026,, no analysts have changed their rating of Enliven Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Enliven Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Enliven Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Enliven Therapeutics, Inc. (ELVN) by visiting AAII Stock Evaluator.

Relative Price Strength of Enliven Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 04, 2026, Enliven Therapeutics, Inc. has a weighted four-quarter relative price strength of 30.32%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Enliven Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Enliven Therapeutics, Inc. Stock Price: Bottom Line

As of August 5, 2026, Enliven Therapeutics, Inc.’s stock price is $58.040, which is down 5.02% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Enliven Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.